Amyloid formation in rat transthyretin: Effect of oxidative stress

Clinica Chimica Acta

Volumn 323, Issue 1-2, 2002, Pages 129-137

  Tajiri, Takahiro ^a   Ando, Yukio ^a   Hata, Kanako ^a   Kamide, Kaeko ^b   Hashimoto, Motonori ^b   Nakamura, Masaaki ^a   Terazaki, Hisayasu ^a   Yamashita, Taro ^a   Kai, Hirofumi ^a   Haraoka, Katsuki ^a   Imasato, Akira ^a   Takechi, Kazuo ^b   Nakagawa, Kazuko ^a   Okabe, Hiroaki ^a   Ishizaki, Takashi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Amyloidogenicity; Modification; Oxidative stress; Purification; Rat; Transthyretin

Indexed keywords

AMYLOID; BUFFER; GLUTATHIONE; PARAQUAT; PREALBUMIN; SULFATE; THIOFLAVINE;

ARTICLE; CONJUGATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; IN VITRO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN PURIFICATION; RAT;

AMYLOID; ANIMALS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HYDROGEN-ION CONCENTRATION; MALE; MICROSCOPY, ELECTRON; OXIDATIVE STRESS; PARAQUAT; PREALBUMIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; SEQUENCE ANALYSIS, PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THIAZOLES;

MUS MUSCULUS;

EID: 0036069276     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00179-1     Document Type: Article

References (56)

1. Human lysozyme gene mutations cause hereditary systemic amyloidosis
2. Transthyretin amyloidosis
3. Redox processes of methionine relevant to beta-amyloid oxidation and Alzheimer's disease
4. Structure and location of amyloid beta peptide chains and arrays in Alzheimer's disease: New findings require reevaluation of the amyloid hypothesis and of tests of the hypothesis
5. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type)
6. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid
7. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
8. Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation
9. Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I [letter]
10. Liver transplantation as a treatment for familial amyloidotic polyneuropathy
11. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin
12. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease
13. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
14. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid
15. Crystal structure of rat transthyretin at 2.5 A resolution: First report on a unique tetrameric structure
16. The primary structure of rabbit and rat prealbumin and a comparison with the tertiary structure of human prealbumin
17. Rat transthyretin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain
18. Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I
19. Transgenic mouse model of familial amyloidotic polyneuropathy
20. Purification and characterization of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy
21. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution
22. Immunocytochemical studies on the localization of plasma and of cellular retinol-binding proteins and of transthyretin (prealbumin) in rat liver and kidney
23. Isolation and characterization of blood group N antigen precursor glycoproteins with Thomsen-Friedenreich (T) activity, N antigen precursor glycoproteins and T-active glycoproteins from cyst fluids of malignant ovarian clear cell carcinoma
24. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease
25. A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme
26. 'In vitro' amyloid fibril formation from transthyretin: The influence of ions and the amyloidogenicity of TTR variants
27. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1
28. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex
29. The interaction of human plasma retinol-binding protein and prealbumin
30. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein
31. Studies on thyroid hormone-binding proteins: II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association
32. Protein-DNA and protein-hormone interactions in prealbumin: A model of the thyroid hormone nuclear receptor?
33. Mechanism of molecular recognition. Structural aspects of 3,3′-diiodo-L-thyronine binding to human serum transthyretin
34. Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
35. Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A
36. Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis
37. Modifications of transthyretin in amyloid fibrils: Analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation
38. Transthyretin microheterogeneity and thyroxine binding are influenced by non-amino acid components and glutathione constituents
39. Posttranslational modification of transthyretin in plasma
40. Oxidative stress and amyloidosis
41. Familial amyloidotic polyneuropathy type I with extracellular superoxide dismutase mutation: A case report
42. Geographical distribution of TTR met30 carriers in northern Sweden: Discrepancy between carrier frequency and prevalence rate
43. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected
44. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal)
45. Familial amyloidotic polyneuropathy in Sweden: Geographical distribution, age of onset, and prevalence
46. Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP) (TTR Met30)
47. Ageing and amyloid fibrillogenesis: Lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide
48. Toxicokinetics of paraquat in humans
49. Correlation between lipid peroxidation and morphological manifestation of paraquat-induced lung injury in rats
50. Effect of preinduction of metallothionein on paraquat toxicity in mice
51. Superoxide-and singlet oxygen-catalyzed lipid peroxidation as a possible mechanism for paraquat (methyl viologen) toxicity
52. Lipid peroxidation: A possible mechanism for paraquat toxicity
53. Oxidative stress is found in amyloid deposits in systemic amyloidosis
54. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy
55. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathological and immunohistochemical similarity to human familial amyloidotic polyneuropathy, type I
56. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I